A Peptide Discovery Company

20n Bio (pr. "twenty-n bio") is a VC-backed startup dedicated to discovering cyclic peptides for therapeutic use. Based in the Greater Philadelphia region, 20n Bio's mission is to address unmet medical needs by leveraging high-throughput screening and chemical optimization to develop peptide drugs across various therapeutic areas.

Our Focus

Peptides combine the advantages of small molecules and antibodies and are increasingly used across modalities including oral peptides, radioligand therapy, and peptide-drug conjugates. However, most approved peptide drugs originate from natural ligands, leaving many high-value targets without suitable binders.

20n Bio addresses this gap with a proprietary discovery platform that screens trillion-scale peptide libraries to identify de novo binders quickly. The platform efficiently explores sequence space to generate hit series with strong binding and selectivity, enabling rapid progression into downstream functional and development workflows.

Alongside our internal programs, we work with pharma and biotech partners through custom discovery, early-hit licensing, and tailored solutions designed to accelerate novel peptide therapeutics.